ALD

ALD Equipment Market worth $6.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, August 12, 2022
Knowledge, Intelligence, ASM International, SME, 3D NAND, IOT, Workforce, Research, CMOS, Power electronics, ALD, COVID-19, Tokyo Electron, Investor, Lam Research, GEM, LED, Gallium arsenide, OLED, CVD, Electronics, Power supply, CAGR, Silicon carbide, Artificial intelligence, RF, Gallium nitride, Indium phosphide, Microelectromechanical systems, Lighting, Internet of things, Logic, NAND, Telecommunication, USD, Adoption, Video game, Marketing, Geography, Automotive industry

CHICAGO, Aug. 12, 2022 /PRNewswire/ -- ALD Equipment Market is projected reach USD 6.0 billion by 2027 from USD 4.1 billion in 2021, at a CAGR of 8.2% during forecast period,according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 12, 2022 /PRNewswire/ -- ALD Equipment Market is projected reach USD 6.0 billion by 2027 from USD 4.1 billion in 2021, at a CAGR of 8.2% during forecast period,according to a new report by MarketsandMarkets.
  • Constantly developing semiconductor industry, proliferation of 3D NAND SSDs, and the advantages offered by ALD are some of the major factors driving the market growing during the forecast period.
  • The growing demand for logic and memory devices for various applications is expected to create opportunities for the adoption of ALD.
  • Plasma-enhanced ALD is highly suited for thin film encapsulation of OLED displays and wafer processing for manufacturing logic and memory devices.

ALD Equipment Market worth $6.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, August 12, 2022
Knowledge, Intelligence, ASM International, SME, 3D NAND, IOT, Workforce, Research, CMOS, Power electronics, ALD, COVID-19, Tokyo Electron, Investor, Lam Research, GEM, LED, Gallium arsenide, OLED, CVD, Electronics, Power supply, CAGR, Silicon carbide, Artificial intelligence, RF, Gallium nitride, Indium phosphide, Microelectromechanical systems, Lighting, Internet of things, Logic, NAND, Telecommunication, USD, Adoption, Video game, Marketing, Geography, Automotive industry

CHICAGO, Aug. 12, 2022 /PRNewswire/ -- ALD Equipment Market is projected reach USD 6.0 billion by 2027 from USD 4.1 billion in 2021, at a CAGR of 8.2% during forecast period,according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 12, 2022 /PRNewswire/ -- ALD Equipment Market is projected reach USD 6.0 billion by 2027 from USD 4.1 billion in 2021, at a CAGR of 8.2% during forecast period,according to a new report by MarketsandMarkets.
  • Constantly developing semiconductor industry, proliferation of 3D NAND SSDs, and the advantages offered by ALD are some of the major factors driving the market growing during the forecast period.
  • The growing demand for logic and memory devices for various applications is expected to create opportunities for the adoption of ALD.
  • Plasma-enhanced ALD is highly suited for thin film encapsulation of OLED displays and wafer processing for manufacturing logic and memory devices.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022

Retrieved on: 
Monday, August 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, FDA, Experiment, Fatty liver disease, Biomarker, FTD, VLCFA, IPF, POC, EUR, ODD, Patent, Disease, Board, Director, USD, Journal of Inherited Metabolic Disease, ALD, IRIS, Adrenoleukodystrophy, Patient, Plasma, NASH, Male, COVID-19, Company, Therapy, Education, Journal of Pharmacology and Experimental Therapeutics, Partnership, PTO, Safety, Lists of diseases, Board of directors, Journal, AMN, Adult, Pharmacokinetics, Pharmaceutical industry, Medical device, Security (finance), Pharmacology, Euronext

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2022.

Key Points: 
  • POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2022.
  • "The next major milestone for Poxel will be the results of our Phase 2 DESTINY-1 study for PXL065 in NASH, which are expected later this quarter.
  • As of June 30, 2022, royalty revenue to Poxel based on TWYMEEG net sales in Japan under the Sumitomo Pharma license agreement has been limited following TWYMEEGs commercial launch on September 16, 2021.
  • As of June 30, 2022, cash and cash equivalents were EUR 16.1 million (USD 16.8 million), as compared to EUR 32.3 million (USD 36.6 million) as of December 31, 2021.

Materion Establishes New Facility to Accelerate Growth in the Semiconductor and Electric Vehicle Markets

Retrieved on: 
Monday, August 1, 2022
Technology, Steel, Semiconductor, Other Energy, Chemicals, Plastics, Manufacturing, Energy, Mining, Minerals, Natural Resources, Acquisition, Corporation, Insurance, Legislation, NYSE, EV, Partnership, Solution, ALD, Safety, COVID-19, Compound, Adoption, Powder, Technology, Company, Beryllium, Annual report, Growth, Risk, Mobile phone, Lithium, Powder metallurgy, Risk management, Materion

Materion Corporation (NYSE: MTRN), a world leader in high-performing advanced materials, announced today that it has established a new facility in Milwaukee, Wisconsin to accelerate the growth of advanced chemical solutions for the semiconductor and electric vehicle (EV) battery markets.

Key Points: 
  • Materion Corporation (NYSE: MTRN), a world leader in high-performing advanced materials, announced today that it has established a new facility in Milwaukee, Wisconsin to accelerate the growth of advanced chemical solutions for the semiconductor and electric vehicle (EV) battery markets.
  • Production capabilities are expected to ramp up during the first half of next year.
  • Following a multi-year R&D partnership, one specific customer is funding $6 million to establish a prototype line in the new Milwaukee facility.
  • Materion, through its wholly owned subsidiaries, supplies highly engineered advanced enabling materials to global markets.

Atomic Layer Deposition Market to Reach US$ 6,587.9 Million by 2030 - Coherent Market Insights

Retrieved on: 
Thursday, July 28, 2022
Sale, Copper, Lam Research, Electronics, ICS, Tokyo Electron, ALD, US, Hitachi, ASM International, CAGR, Oxygen, Salinity, Analysis, Growth, Lithium, Aluminium, Palladium, Kumamoto Prefecture

The growth of power electronics also facilitates the development of atomic layer deposition technologies.

Key Points: 
  • The growth of power electronics also facilitates the development of atomic layer deposition technologies.
  • For the same, atomic layer deposition (ALD) can substantially improve the reliability and performance of these components.
  • The global atomic layer deposition market is expected to exhibit a CAGR of 15.4% over the forecast period (2022-2030).
  • Technology launches, acquisitions, collaborations and R&D activities are key strategies adopted by players in the global atomic layer deposition market.

Atomic Layer Deposition Market to Reach US$ 6,587.9 Million by 2030 - Coherent Market Insights

Retrieved on: 
Thursday, July 28, 2022
Sale, Copper, Lam Research, Electronics, ICS, Tokyo Electron, ALD, US, Hitachi, ASM International, CAGR, Oxygen, Salinity, Analysis, Growth, Lithium, Aluminium, Palladium, Kumamoto Prefecture

The growth of power electronics also facilitates the development of atomic layer deposition technologies.

Key Points: 
  • The growth of power electronics also facilitates the development of atomic layer deposition technologies.
  • For the same, atomic layer deposition (ALD) can substantially improve the reliability and performance of these components.
  • The global atomic layer deposition market is expected to exhibit a CAGR of 15.4% over the forecast period (2022-2030).
  • Technology launches, acquisitions, collaborations and R&D activities are key strategies adopted by players in the global atomic layer deposition market.

Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

Retrieved on: 
Tuesday, July 19, 2022
NASH, Research, Adult, Non-alcoholic fatty liver disease, ALD, AMN, Disease, Patient, Security (finance), Plasma, SAN, Pharmacokinetics, U.S. Securities and Exchange Commission, Safety, Therapy, MAD, Review, Degenerative disease, Fibrosis, Private Securities Litigation Reform Act, Forward-looking statement, SAD, Twitter, Risk, Adrenoleukodystrophy, NAFLD, Brain, Metabolism, ABCD2, Apolipoprotein B, Government budget balance, Male, NASDAQ, Multimedia, GIP, ABCD1, Lists of diseases, Death, Annual report, FDA, Agency, X-ALD, Clinical trial, C-peptide, VLCFA, Triglyceride, Pharmaceutical industry

SAN DIEGO, July 19, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the FDA has lifted the clinical hold placed on the clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). As a result, the company expects to resume study enrollment in the coming weeks.

Key Points: 
  • The FDA lifted the clinical hold following its review of results from an in vivo genotoxicity study that it had requested due to the study being conducted with multiple doses in patients.
  • Viking had planned to conduct this study prior to Phase 2 but accelerated its execution based on FDA's request.
  • The company does not believe that the long-term development timeline for VK0214 has been significantly impacted by the temporary clinical hold.
  • The Phase 1b study of VK0214 is designed to enroll patients with the adrenomyeloneuropathy (AMN) form of X-ALD.

Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770

Retrieved on: 
Tuesday, July 5, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, NASH, Patient, ABCD1, HSCT, Gait, Growth, Company, Lists of diseases, Haemophilia, Pioglitazone, Euronext Paris, AMPK, Therapy, AMN, Spinal cord, White matter, Fatty liver disease, Metabolic disorder, TZD, Prevalence, Woman, Chronic inflammatory demyelinating polyneuropathy, Journal of Inherited Metabolic Disease, Experiment, Brain, Journal of Pharmacology and Experimental Therapeutics, Degenerative disease, Phenotype, Man, Peroxisome, Inflammation, Peripheral nervous system, Partnership, Weakness, Adrenoleukodystrophy, POC, Sciatic nerve, Cell, Adenosine, Death, Hematopoietic stem cell transplantation, Journal, Incontinence, VLCFA, Metabolism, Disease, Plasma, ALD, Publication, Risk, Pathology, Pharmaceutical industry, Medical device, Imeglimin, Euronext, Pharmacology

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.
  • An article on PXL065 has been published in The Journal of Inherited Metabolic Disease (JIMD) and is entitled Therapeutic potential of deuterium-stabilized (R)-pioglitazone - PXL065 - for X-linked adrenoleukodystrophy.
  • These publications describe similar beneficial preclinical profiles of PXL770 and PXL065 in models of ALD.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Forge Nano and Anovion Partner to Help Propel U.S. Battery Tech and Strengthen Domestic Supply Chain

Retrieved on: 
Tuesday, June 28, 2022
Engineering, GLOBE, Party, Atomic layer deposition, Company, ALD, Original equipment manufacturer, Partnership, Technology, Orbit, Graphite, EVS, Lithium, Electric battery

The companies will use Forge Nano's proprietary technology , with Anovion's combined 140+ years of synthetic graphite manufacturing and experience, to secure domestic energy initiatives and alleviate supply chain issues.

Key Points: 
  • The companies will use Forge Nano's proprietary technology , with Anovion's combined 140+ years of synthetic graphite manufacturing and experience, to secure domestic energy initiatives and alleviate supply chain issues.
  • Forge Nano's surface engineering platform technology will be used to apply specialized coatings to Anovion's synthetic graphite battery materials.
  • "This exciting partnership with industry leader, Forge Nano, helps us supply the market with another critical product line.
  • We're proud to be joining forces to help solve the critical need for a domestic supply of battery materials."

Anovion and Forge Nano Sign Strategic Partnership to Strengthen the U.S. Domestic Graphite Anode Battery Materials Supply Chain

Retrieved on: 
Monday, June 27, 2022
Air Liquide, View, Atomic layer deposition, Company, Industry, ALD, Original equipment manufacturer, Volkswagen, BMTC, Partnership, LLC, Technology, Orbit, Graphite, Government, Safety, Program, Multimedia, Electrode, Lithium

CHICAGO and DENVER, June 27, 2022 /PRNewswire/ -- Anovion, LLC (Anovion) and Forge Nano Inc. (Forge Nano), two premier U.S. domestic battery materials manufacturers, announce an agreement to collaborate on the supply of enhanced graphite anode technology for lithium-ion batteries. The companies will use Forge Nano's proprietary particle coating technology and Anovion's proven synthetic graphite manufacturing processes to secure domestic energy initiatives and alleviate supply chain issues.

Key Points: 
  • CHICAGO and DENVER, June 27, 2022 /PRNewswire/ -- Anovion, LLC ( Anovion ) and Forge Nano Inc. ( Forge Nano ), two premier U.S. domestic battery materials manufacturers, announce an agreement to collaborate on the supply of enhanced graphite anode technology for lithium-ion batteries.
  • Forge Nano's surface engineering platform technology will be used to apply specialized coatings and enhanced capabilities to Anovion's synthetic graphite battery materials.
  • Forge Nano and Anovion will also establish a long-term supply agreement for synthetic graphite anode materials for Forge Nano's Made-in-America lithium-ion cells.
  • As a leader in synthetic graphite lithium-ion battery anode materials innovation and manufacturing, Anovion has the largest domestic commercial production today.